Skip to main
IMUX

Immunic Inc (IMUX) Stock Forecast & Price Target

Immunic Inc (IMUX) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immunic is in a strong position with their lead asset vidofludimus calcium, which has shown positive results in both their Phase 2 EMPhASIS trial and with their recently announced Phase 3 ENSURE program in relapsing-remitting multiple sclerosis. Despite a capital-intensive nature of their late-stage program, their recent financing of $187M and continued investment in R&D should support an NDA filing in 2027, making it a potential favorable investment opportunity.

Bears say

Immunic is a clinical-stage biopharmaceutical company that is developing a pipeline of selective oral immunology therapies for chronic inflammatory and autoimmune diseases, but there are several risk factors that could potentially hinder their success in the market, such as clinical and regulatory challenges, financial risks, and competition in the market. Additionally, the financing deal with pre-funded warrants and potential dilution could impact their financial stability. However, their potential for targeting disease modification and their plans for upcoming Phase 3 trials could position them well for future success.

Immunic Inc (IMUX) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunic Inc (IMUX) Forecast

Analysts have given Immunic Inc (IMUX) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Immunic Inc (IMUX) has a Strong Buy consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunic Inc (IMUX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.